Combination treatment for locally advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy and immunotherapy, followed by radiation, for people with locally advanced pancreatic cancer. The goal is to see if this approach can shrink the tumor enough to make it removable by surgery, potentially offering a better chance of a cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of pancreatic cancer.
- You should have received no previous cancer treatment.
- Your cancer must be locally advanced, meaning it has not spread to distant organs.
- You need to be in generally good physical health (you can do most of your daily activities).
- You cannot have certain medical conditions like an autoimmune disease or a bleeding disorder.
- You must be willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial combines focused radiation with a chemotherapy drug combo to help shrink or control locally advanced pancreatic cancer. If it works, this treatment might make the tumor smaller and improve quality of life.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
Hear when a new Locally Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.